Updated December 7, 2021
Monoclonal antibodies are laboratory-made proteins that can be given as treatment to aid the immune system’s ability to prevent or minimize infections by germs such as viruses. Treatment with monoclonal antibody therapy can prevent COVID-19 or make its symptom course more mild.
The FDA has issued Emergency Use Authorizations (EUAs) for multiple products (see additional information below) for treatment for COVID-19 in patients with mild to moderate symptoms that are at high risk for progression to severe COVID-19 and/or hospitalization. The FDA has also authorized use of some of monoclonal antibody products to prevent disease in people who have been exposed to the SARS-CoV-2 virus and have not yet developed symptoms but are at high risk for severe COVID-19. Prophylaxis with these products is not a substitute for vaccination against COVID-19. Monoclonal antibodies are not authorized for use in hospitalized patients.
Monoclonal Antibody Treatment Options in Orange County
There is currently a national shortage of monoclonal antibody. Due to this shortage, the Department of Health and Human Services has transitioned from allowing providers to directly order doses from the supplier to a model wherein doses are allocated through state health departments.
Orange County providers who wish to request anti-SARS-COV-2 monoclonal antibody product for use to treat patients at their healthcare facility are advised to submit a Resource Request form on a weekly basis to: www.ochealthinfo.com/ems/aoc.
Given the current shortages, providers should not expect fulfillment of their entire request. Some providers may not receive any allocation as this will depend on the amount allocated to our county.
CDPH is also sponsoring monoclonal antibody access sites at the following locations:
- Hawaiian Gardens MAB & Testing Center
- 21530 Pioneer Blvd
- Hawaiian Gardens, CA 90716
- Monday – Saturday: 8am to 6pm
Monoclonal antibody treatment is available by appointment only. Patients and providers can make an appointment by calling (209) 494-6318.
- ContinuEM Urgent Care
- 6430 South Street
- Lakewood, CA 90713
- Monday - Friday, 9am to 10:30pm
- Saturday and Sunday: 10am to 5pm
Monoclonal antibody treatment is available by appointment only. Patients and providers can make an appointment by calling (562) 731-3990.
Treatment Recommendations for Providers during the Current Monoclonal Antibody Shortage
On November 1, 2021, the California Department of Public Health (CDPH) released updated recommendations for medical providers for the use of anti-SARS-CoV-2 monoclonal antibodies. This guidance outlines recommendations for the use of these products in treatment and post-exposure prophylaxis during the current national shortages and also details the current national plans for product distribution by HHS.
The currently available anti-SARS-CoV-2 monoclonal antibodies that have received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) and are available for use in California include:
- Bamlanivimab/etesevimab – This product is administered intravenously and approved for use as a treatment or as a post-exposure prophylaxis. (Bamlanivimab/etesevimab EUA)
- Casirivimab/imdevimab (REGENCOV) – All available forms of casirivimab/imdevimab may be administered either subcutaneously or by IV infusion. Instructions for preparation for each route of administration can be found in the Dosage and Administration section of the product EUA. Approved for use as a treatment or as a post-exposure prophylaxis. (Casirivimab/imdevimab EUA)
- Sotrovimab – This product can be administered intravenously and is approved for use as a treatment. (Sotrovimab EUA)
Providers using these products should carefully review the EUAs (links above) for treatment criteria, dosing, and administration guidance.